Arkansas is facing a spike in COVID-19 cases, but independent pharmacies in the state are struggling to keep up with the demand for the antiviral medication Paxlovid. The federal government initially provided the medication for free, but now it is being sold commercially by Pfizer for an average of $1,400. While Medicare, Medicaid, and uninsured patients can still get Paxlovid for free, many pharmacies are not stocking it due to high upfront costs and low reimbursements from insurance companies.
Pharmacists across the state report a surge in calls from sick patients, but they are often unable to find Paxlovid in stock. The situation highlights broader issues in the pharmaceutical industry, particularly regarding pharmacy benefit managers (PBMs) who set drug prices. Small pharmacies are struggling to stay afloat due to low reimbursements for medications like Paxlovid, leading to limited supplies and access issues for patients.
Federal lawmakers are exploring ways to address the problems caused by PBMs, as independent pharmacies continue to face challenges in stocking essential medications. Efforts in Arkansas to regulate PBMs have had limited success, and the situation underscores the need for comprehensive reform in the pharmaceutical industry to ensure patients can access necessary medications. Despite claims from officials that there are no widespread shortages of Paxlovid, pharmacies are struggling to keep up with the demand, raising concerns about access to vital treatments for COVID-19.
Source
Photo credit arktimes.com